One confirmed case needs at least dozens of test kits for contact tracing - and get this - not once, but a bare minimum of three times: once before the quarantine, and twice after. What' s more, antigen test kits that Biolidics sells are specifically needed for testing the effectiveness of vaccines. It gets better: currently, PCR test kits, the gold-standard of clinical testing, takes a long time and requires bulky machinery. However, news of Epidax, a one-of-a-kind highly portable, rapid, microfluidics-based PCR test kit released by Professor Lim Chwee Teck himself on 29 June 2020 - that has shown to be as accurate or even more accurate than clinical PCR test kits - is undergoing patenting and commercialisation, and is set to become the standard testing kit seen at airports, businesses, and within the community. If you don' t know what microfluidics is, it is a multidisciplinary field that involves engineering, physics, chemistry, biochemistry, nanotechnology, and biotechnology. Only Prof Lim, with his multitude of papers, innovative inventions and his wide breadth of knowledge in Science along with a dedicated team of some of Singapore' s university' s best researchers has come up with something like this. If you can see the need for testing kits, just ask yourself one question: which other company is making record sales of test kits nowadays?

 

Flash news:

" Singapore may have to consider replacing 2-week Covid-19 isolation with " rigorous testing regime for travellers" https://bit.ly/3iEXYlx - you can be assured of an ever-increasing test kit demand.

 

And Biolidics' glory doesn' t end there. According to this link: https://www.sgx.com/research-education/market-updates/20181219-biolidics-clearbridge-health-spinoff-lists-catalist, there will be " increased awareness and adoption of liquid biopsy - [t]he liquid biopsy market is expected to grow from approximately US$0.6 billion in 2016 to US$1.7 billion in 2021, at a compound annual growth rate of 23.4%" . Do you know how revolutionary Biolidics' Clear Cell FX1 system is? If you know anything about cancer testing, it requires taking a chunk of your flesh off you and that' s not without its risks, costs, or challenges. The new system can do cancer diagnostics with just an ordinary blood sample. Will you send in an extra, small vial of blood for a quick cancer checkup? Seems like a no-brainer versus having to bear with an underlying silent killer that, by the time you notice it some other way, it' s too late. No wonder Biolidics has has been accorded the prestigious " IPOS Award for IP Champions" by WIPO-IPOS, has already broken into the Chinese market with their own wholly-owned subsidiary in Shanghai, and is in a collaboration agreement with LC-Bio Technologies (Hangzhou) Co., Ltd. (&ldquo LC-Bio&rdquo ) for the development of innovative diagnostic solutions at LC-Bio&rsquo s medical laboratory in China, using the Company&rsquo s proprietary technology.

 

You may also be heartened to know that Biolidics has over 8.6 million in cash and cash equivalents and has only 260 million shares.

 

Vicplas is another gem to simultaneously keep an eye on. Vicplas has Forefront Medical Technologies, Arrow Medical and XentiQ their medical devices manufacturing, injection moulding and 3D printing capabilities could be in high demand during the COVID period. When one person gets COVID, they use a whole slew of medical devices. Guess what? Forefront Medical Technologies produces everything you need. From diagnostics, to medical devices, to drug delivery systems, from design to prototyping to testing to manufacturing and shipping - they are a one-stop global solution for anyone in the medical business. Perhaps you would like to spend some time checking out their website http://forefrontmedical.com/ and maybe watch some of their videos: http://forefrontmedical.com/videos/

 

COVID is getting more infections and more serious. People with COVID are beginning to relapse into respiratory issues. Will this be for life? Will drugs and medical devices support always be a necessity?

 

Vicplas' injection moulding capabilities also means that they are one of the few companies selected by the Singapore government themselves to produce the tens of millions of test kits needed. And you can be assured that the world will need many more test kits for the crisis to be truly over.

 

For those of you who' ve taken profit from Medtecs and UG healthcare, or think that these two stocks won' t grow much over the next year, or next few years, Biolidics and Vicplas are the SGX stocks to look at.

 

They are working to combat COVID with test kits and medical devices, and are our hope in the battle against this deadly disease. We need them to keep up their efforts and work together with governments and healthcare providers all around the world so that this crisis can eventually be resolved.

 

 

 

One confirmed case needs at least dozens of test kits for contact tracing - and get this - not once, but a bare minimum of three times: once before the quarantine, and twice after. What' s more, antigen test kits that Biolidics sells are specifically needed for testing the effectiveness of vaccines. It gets better: currently, PCR test kits, the gold-standard of clinical testing, takes a long time and requires bulky machinery. However, news of Epidax, a one-of-a-kind highly portable, rapid, microfluidics-based PCR test kit released by Professor Lim Chwee Teck himself on 29 June 2020 - that has shown to be as accurate or even more accurate than clinical PCR test kits - is undergoing patenting and commercialisation, and is set to become the standard testing kit seen at airports, businesses, and within the community. If you don' t know what microfluidics is, it is a multidisciplinary field that involves engineering, physics, chemistry, biochemistry, nanotechnology, and biotechnology. Only Prof Lim, with his multitude of papers, innovative inventions and his wide breadth of knowledge in Science along with a dedicated team of some of Singapore' s university' s best researchers has come up with something like this. If you can see the need for testing kits, just ask yourself one question: which other company is making record sales of test kits nowadays?

 

Flash news:

" Singapore may have to consider replacing 2-week Covid-19 isolation with " rigorous testing regime for travellers" https://bit.ly/3iEXYlx - you can be assured of an ever-increasing test kit demand.

 

And Biolidics' glory doesn' t end there. According to this link: https://www.sgx.com/research-education/market-updates/20181219-biolidics-clearbridge-health-spinoff-lists-catalist, there will be " increased awareness and adoption of liquid biopsy - [t]he liquid biopsy market is expected to grow from approximately US$0.6 billion in 2016 to US$1.7 billion in 2021, at a compound annual growth rate of 23.4%" . Do you know how revolutionary Biolidics' Clear Cell FX1 system is? If you know anything about cancer testing, it requires taking a chunk of your flesh off you and that' s not without its risks, costs, or challenges. The new system can do cancer diagnostics with just an ordinary blood sample. Will you send in an extra, small vial of blood for a quick cancer checkup? Seems like a no-brainer versus having to bear with an underlying silent killer that, by the time you notice it some other way, it' s too late. No wonder Biolidics has has been accorded the prestigious " IPOS Award for IP Champions" by WIPO-IPOS, has already broken into the Chinese market with their own wholly-owned subsidiary in Shanghai, and is in a collaboration agreement with LC-Bio Technologies (Hangzhou) Co., Ltd. (&ldquo LC-Bio&rdquo ) for the development of innovative diagnostic solutions at LC-Bio&rsquo s medical laboratory in China, using the Company&rsquo s proprietary technology.

 

You may also be heartened to know that Biolidics has over 8.6 million in cash and cash equivalents and has only 260 million shares.

 

Vicplas is another gem to simultaneously keep an eye on. Vicplas has Forefront Medical Technologies, Arrow Medical and XentiQ their medical devices manufacturing, injection moulding and 3D printing capabilities could be in high demand during the COVID period. When one person gets COVID, they use a whole slew of medical devices. Guess what? Forefront Medical Technologies produces everything you need. From diagnostics, to medical devices, to drug delivery systems, from design to prototyping to testing to manufacturing and shipping - they are a one-stop global solution for anyone in the medical business. Perhaps you would like to spend some time checking out their website http://forefrontmedical.com/ and maybe watch some of their videos: http://forefrontmedical.com/videos/

 

COVID is getting more infections and more serious. People with COVID are beginning to relapse into respiratory issues. Will this be for life? Will drugs and medical devices support always be a necessity?

 

Vicplas' injection moulding capabilities also means that they are one of the few companies selected by the Singapore government themselves to produce the tens of millions of test kits needed. And you can be assured that the world will need many more test kits for the crisis to be truly over.

 

For those of you who' ve taken profit from Medtecs and UG healthcare, or think that these two stocks won' t grow much over the next year, or next few years, Biolidics and Vicplas are the SGX stocks to look at.

 

They are working to combat COVID with test kits and medical devices, and are our hope in the battle against this deadly disease. We need them to keep up their efforts and work together with governments and healthcare providers all around the world so that this crisis can eventually be resolved.

 

 

 

One confirmed case needs at least dozens of test kits for contact tracing - and get this - not once, but a bare minimum of three times: once before the quarantine, and twice after. What' s more, antigen test kits that Biolidics sells are specifically needed for testing the effectiveness of vaccines. It gets better: currently, PCR test kits, the gold-standard of clinical testing, takes a long time and requires bulky machinery. However, news of Epidax, a one-of-a-kind highly portable, rapid, microfluidics-based PCR test kit released by Professor Lim Chwee Teck himself on 29 June 2020 - that has shown to be as accurate or even more accurate than clinical PCR test kits - is undergoing patenting and commercialisation, and is set to become the standard testing kit seen at airports, businesses, and within the community. If you don' t know what microfluidics is, it is a multidisciplinary field that involves engineering, physics, chemistry, biochemistry, nanotechnology, and biotechnology. Only Prof Lim, with his multitude of papers, innovative inventions and his wide breadth of knowledge in Science along with a dedicated team of some of Singapore' s university' s best researchers has come up with something like this. If you can see the need for testing kits, just ask yourself one question: which other company is making record sales of test kits nowadays?

 

Flash news:

" Singapore may have to consider replacing 2-week Covid-19 isolation with " rigorous testing regime for travellers" https://bit.ly/3iEXYlx - you can be assured of an ever-increasing test kit demand.

 

And Biolidics' glory doesn' t end there. According to this link: https://www.sgx.com/research-education/market-updates/20181219-biolidics-clearbridge-health-spinoff-lists-catalist, there will be " increased awareness and adoption of liquid biopsy - [t]he liquid biopsy market is expected to grow from approximately US$0.6 billion in 2016 to US$1.7 billion in 2021, at a compound annual growth rate of 23.4%" . Do you know how revolutionary Biolidics' Clear Cell FX1 system is? If you know anything about cancer testing, it requires taking a chunk of your flesh off you and that' s not without its risks, costs, or challenges. The new system can do cancer diagnostics with just an ordinary blood sample. Will you send in an extra, small vial of blood for a quick cancer checkup? Seems like a no-brainer versus having to bear with an underlying silent killer that, by the time you notice it some other way, it' s too late. No wonder Biolidics has has been accorded the prestigious " IPOS Award for IP Champions" by WIPO-IPOS, has already broken into the Chinese market with their own wholly-owned subsidiary in Shanghai, and is in a collaboration agreement with LC-Bio Technologies (Hangzhou) Co., Ltd. (&ldquo LC-Bio&rdquo ) for the development of innovative diagnostic solutions at LC-Bio&rsquo s medical laboratory in China, using the Company&rsquo s proprietary technology.

 

You may also be heartened to know that Biolidics has over 8.6 million in cash and cash equivalents and has only 260 million shares.

 

Vicplas is another gem to simultaneously keep an eye on. Vicplas has Forefront Medical Technologies, Arrow Medical and XentiQ their medical devices manufacturing, injection moulding and 3D printing capabilities could be in high demand during the COVID period. When one person gets COVID, they use a whole slew of medical devices. Guess what? Forefront Medical Technologies produces everything you need. From diagnostics, to medical devices, to drug delivery systems, from design to prototyping to testing to manufacturing and shipping - they are a one-stop global solution for anyone in the medical business. Perhaps you would like to spend some time checking out their website http://forefrontmedical.com/ and maybe watch some of their videos: http://forefrontmedical.com/videos/

 

COVID is getting more infections and more serious. People with COVID are beginning to relapse into respiratory issues. Will this be for life? Will drugs and medical devices support always be a necessity?

 

Vicplas' injection moulding capabilities also means that they are one of the few companies selected by the Singapore government themselves to produce the tens of millions of test kits needed. And you can be assured that the world will need many more test kits for the crisis to be truly over.

 

For those of you who' ve taken profit from Medtecs and UG healthcare, or think that these two stocks won' t grow much over the next year, or next few years, Biolidics and Vicplas are the SGX stocks to look at.

 

They are working to combat COVID with test kits and medical devices, and are our hope in the battle against this deadly disease. We need them to keep up their efforts and work together with governments and healthcare providers all around the world so that this crisis can eventually be resolved.